[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.175.236. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News & Perspectives
May 21, 2008

Cholesterol Drug Controversy Continues

JAMA. 2008;299(19):2266. doi:10.1001/jama.299.19.2266

Chicago—Controversy over the use of ezetimibe/simvastatin to prevent progression of atherosclerosis continues to grow.

At the American Academy of Cardiology's 57th Annual Scientific Session here in March, attendees packed the lecture hall to hear a detailed account of the ENHANCE (Effect of Ezetimibe Plus Simvastatin vs Simvastatin Alone on Atherosclerosis in the Carotid Artery) trial, 2 months after the company released the study's major findings to the media rather than to the scientific community. After the presentation, a panel assembled by the academy to put the findings in perspective declared that the aggressively marketed drug combination should be used only as a last resort in treating patients to decrease their levels of low-density lipoprotein cholesterol (LDL-C).

First Page Preview View Large
First page PDF preview
First page PDF preview
×